Donald Engelman
Donald M. Engelman (born 1941) is Higgins Professor of Biochemistry at Yale University. He is a member of the National Academy of Sciences (1997), fellow of the American Academy of Arts and Sciences,[1] a fellow of the National Institutes of Health, and has been a Guggenheim fellow.[2] He is a director of the Stryker Corporation.[3] He is involved in the creation of new cancer drugs and treatments.[4] For example, Engelman is involved in research to use peptides to aid in destroying tumors.[5]
Administration, Advising, and Consulting
Engelman has served as Director of Biological Sciences at Yale, an advisor to the Brookhaven National Laboratory, and a consultant to the Los Alamos National Laboratory.[6] He also served as Acting Dean of Yale College in 1991.[7]
Education
Engelman is a graduate (and trustee[8]) of Reed College and Yale University.[9]
Engelman Lab
Engelman directs the Engelman Laboratory at Yale.[10]
Patents
Engelman holds six United States patents for his discoveries.[11]
References
- ^ "REED COLLEGE AMERICAN ACADEMY OF ARTS AND SCIENCES AWARDS".
- ^ "All Fellows - John Simon Guggenheim Memorial Foundation". Gf.org. Retrieved 2011-07-06.
- ^ "Donald M. Engelman Profile - Forbes.com". People.forbes.com. Retrieved 2011-07-06.
- ^ redOrbit. "URI Research Couple's Method Targets Cancerous Tumors - Redorbit". Redorbit.
- ^ http://www.healthimaging.com/index.php?option=com_articles&article=19339
- ^ "Reed Magazine: News of the College".
- ^ "A Yale College Dean Is Named". The New York Times. 1991-10-15.
- ^ "List of Public Companies Worldwide, Letter - Businessweek - Businessweek". Businessweek.com.
- ^ "The Engelman Lab - Donald M. Engelman". Yale.edu. Retrieved 2011-07-06.
- ^ "The Engelman Lab". Yale.edu. Retrieved 2011-07-06.
- ^ "Donald M Engelman, Page 1".